Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension-Reference-Cited by-同舟云学术

Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension

Published:2013-07-30 Issue:5 Volume:128 Page:512-523
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Hadri Lahouaria¹,Kratlian Razmig G.¹,Benard Ludovic¹,Maron Bradley A.¹,Dorfmüller Peter¹,Ladage Dennis¹,Guignabert Christophe¹,Ishikawa Kiyotake¹,Aguero Jaume¹,Ibanez Borja¹,Turnbull Irene C.¹,Kohlbrenner Erik¹,Liang Lifan¹,Zsebo Krisztina¹,Humbert Marc¹,Hulot Jean-Sébastien¹,Kawase Yoshiaki¹,Hajjar Roger J.¹,Leopold Jane A.¹

Affiliation:

1. From the Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY (L.H., R.G.K., L.B., D.L., K.I., J.A., I.C.T., E.K., L.L., J.-S.H., Y.K., R.J.H.); Cardiovascular Medicine Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (B.A.M., J.A.L.); Hôpital Antoine-Béclère, Clamart, France (P.D., C.G., M.H.); INSERM U999, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France (P.D., M.H.); Fundación Centro Nacional de Investigaciones...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference42 articles.

1. Looking to the future: a new decade of pulmonary arterial hypertension therapy

2. Molecular Mechanisms of Pulmonary Arterial Hypertension

3. Pathology of pulmonary hypertension

4. The study of risk in pulmonary arterial hypertension

5. Sarco/Endoplasmic Reticulum Ca 2+ -ATPase Gene Transfer Reduces Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary hypertension;Nature Reviews Disease Primers;2024-01-04

2. CDN1163 alleviates SERCA2 dysfunction-induced pulmonary vascular remodeling by inhibiting the phenotypic transition of pulmonary artery smooth muscle cells;Clinical and Experimental Hypertension;2023-10-29

3. Pulmonary vascular fibrosis in pulmonary hypertension – The role of the extracellular matrix as a therapeutic target;Pharmacology & Therapeutics;2023-07

4. Silencing EIF3A ameliorates pulmonary arterial hypertension through HDAC1 and PTEN/PI3K/AKT pathway in vitro and in vivo;Experimental Cell Research;2023-05

5. Acquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension;Frontiers in Cell and Developmental Biology;2023-02-02